AAP IMPLANTATE AG aap Implantate AG / aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ® growth in H1/2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) generated sales totalling EUR 6.5 million in the second quarter of 2015 (Q2/2014: EUR 8.1 million) according to preliminary figures, thereby exceeding the guidance provided in May of EUR 5.0 million to EUR 6.1 million. Total sales in the first half of the current financial year thus amounted to EUR 13.6 million (H1/2014: EUR 14.2 million).
Sales in EUR million | Q2/2015 | Q2/2014 | Change |
| Trauma | 3.2 | 2.9 | 8% |
| thereof LOQTEQ® | 2.0 | 1.8 | 15% |
| Biomaterials | 3.2 | 4.9 | -34% |
| Projects | 0.0 | 0.1 | -82% |
| Other | 0.1 | 0.2 | -50% |
| Total sales | 6.5 | 8.1 | -20% |
Sales in EUR million | H1/2015 | H1/2014 | Change |
| Trauma | 5.6 | 5.1 | 11% |
| thereof LOQTEQ® | 3.7 | 2.9 | 27% |
| Biomaterials | 7.6 | 8.4 | -9% |
| Projects | 0.2 | 0.2 | 10% |
| Other | 0.2 | 0.5 | -72% |
| Total sales | 13.6 | 14.2 | -4% |
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ® a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
